Cover
Cover | 12 Months Ended |
Dec. 31, 2022 | |
Document Information [Line Items] | |
Document Type | DEF 14A |
Amendment Flag | false |
Entity Information [Line Items] | |
Entity Registrant Name | AMGEN INC. |
Entity Central Index Key | 0000318154 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure | 12 Months Ended | ||
Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
Pay vs Performance Disclosure [Table] | |||
Pay vs Performance [Table Text Block] | Pay Versus Performance As required, below is disclosure of the compensation of the Company’s Named Executive Officers, or NEOs, for the last three fiscal years calculated in accordance with the recently adopted Item 402(v) of Regulation S-K. year, and vesting For information about our compensation philosophy and how we align executive compensation with our performance, please see our Compensation Discussion and Analysis. Year Value of Initial Fixed $100 Summary Compensation (1)(2) Average non-CEO Average Non-CEO (1)(2) Amgen Total (3) Peer Group (3)(4) Net Non-GAAP (5) 2022 21,399,733 41,655,553 7,211,427 12,777,767 119.07 140.14 6,552 17.69 2021 21,721,154 17,040,728 7,358,134 5,869,521 98.87 126.48 5,893 17.10 2020 20,131,408 14,724,312 6,736,942 5,571,375 98.01 102.57 7,264 16.60 (1) As the valuation methods for “compensation actually paid” required by the SEC differ from those required in the Summary Compensation Table (“SCT”), the table below provides a reconciliation of SCT amounts to the Compensation Actually Paid (“CAP”) amounts in the Pay Versus Performance table for Mr. Bradway and the average SCT and CAP amounts for our other NEOs for each of the last three fiscal years. The other non-CEO Summary Compensation Table to Compensation Actually Paid Reconciliation Table Required Adjustments to Summary Compensation Table (“SCT”) Totals to Determine Year SCT SCT Value SCT Value of $) Fair Value as Year-Over-Year Increase CAP Formula and A B C D E F G=A-B-C+D+E+F Robert A. Bradway 2022 21,399,733 11,138,544 4,773,714 20,800,961 11,751,273 3,615,844 41,655,553 2021 21,721,154 11,138,622 4,773,710 13,805,997 (2,572,161 ) (1,930 ) 17,040,728 2020 20,131,408 10,079,676 4,319,993 13,341,787 (3,546,758 ) (802,456 ) 14,724,312 Average of Other NEOs 2022 7,211,427 3,184,719 1,364,984 5,947,522 3,219,024 949,497 12,777,767 2021 7,358,134 3,246,014 1,391,226 4,023,392 (640,566 ) (234,199 ) 5,869,521 2020 6,736,942 2,834,702 1,214,968 3,752,153 (650,362 ) (217,688 ) 5,571,375 (2) Stock option fair values are calculated at each measurement date using a Black-Scholes valuation model, consistent with the approach used to value the awards at the grant date. Stock option fair values as of each measurement date were determined using updated assumptions (the closing stock price of our Common Stock as of the measurement date, risk-free interest rate, expected life, expected volatility of the price of our Common Stock, and expected dividend yield) and fair value increases are primarily driven by an increase in the price of the Company’s Common Stock. Performance unit fair values are calculated using a payout simulation model, consistent with the approach used to value the awards at the grant date. Performance unit fair values as of each measurement date were determined using updated assumptions (risk-free interest rate, volatility of the price of our Common Stock, the closing price of our Common Stock on the measurement date, volatilities of the prices of the stocks of the Reference Group (as defined in footnote 3 to the “Grant of Plan-Based Awards” table in our Executive Compensation Tables), and the correlations of returns of our Common Stock and the stocks of the Reference Group to simulate total shareholder returns and their resulting impact on the payout percentages based on the contractual terms of the performance units) and fair value increases are primarily driven by an increase in the price of the Company’s Common Stock. (3) Pursuant to the SEC rules, total shareholder return, or TSR, reflects an initial investment of $100 on December 31, 2019. All values assume reinvestment of the pretax value of dividends, are calculated as of December 31 of each year, and are weighted according to the respective issuers’ stock market capitalization at the beginning of each period for which a return is indicated. (4) The peer group for each listed fiscal year consists of the companies listed as our executive compensation benchmarking peer group in the Compensation Discussion and Analysis specific for that year. For 2020, the companies included: Allergan plc (until July 2020); Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Celgene Corporation (until July 2020); Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A.. For 2021 and 2022, the peer group included: Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A. (5) Non-Generally non-GAAP, Appendix B | ||
Company Selected Measure Name | non-GAAP, earnings per share | ||
Named Executive Officers, Footnote [Text Block] | The other non-CEO | ||
Peer Group Issuers, Footnote [Text Block] | The peer group for each listed fiscal year consists of the companies listed as our executive compensation benchmarking peer group in the Compensation Discussion and Analysis specific for that year. For 2020, the companies included: Allergan plc (until July 2020); Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Celgene Corporation (until July 2020); Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A.. For 2021 and 2022, the peer group included: Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A. | ||
PEO Total Compensation Amount | $ 21,399,733 | $ 21,721,154 | $ 20,131,408 |
PEO Actually Paid Compensation Amount | $ 41,655,553 | 17,040,728 | 14,724,312 |
Adjustment To PEO Compensation, Footnote [Text Block] | Summary Compensation Table to Compensation Actually Paid Reconciliation Table Required Adjustments to Summary Compensation Table (“SCT”) Totals to Determine Year SCT SCT Value SCT Value of $) Fair Value as Year-Over-Year Increase CAP Formula and A B C D E F G=A-B-C+D+E+F Robert A. Bradway 2022 21,399,733 11,138,544 4,773,714 20,800,961 11,751,273 3,615,844 41,655,553 2021 21,721,154 11,138,622 4,773,710 13,805,997 (2,572,161 ) (1,930 ) 17,040,728 2020 20,131,408 10,079,676 4,319,993 13,341,787 (3,546,758 ) (802,456 ) 14,724,312 Average of Other NEOs 2022 7,211,427 3,184,719 1,364,984 5,947,522 3,219,024 949,497 12,777,767 2021 7,358,134 3,246,014 1,391,226 4,023,392 (640,566 ) (234,199 ) 5,869,521 2020 6,736,942 2,834,702 1,214,968 3,752,153 (650,362 ) (217,688 ) 5,571,375 | ||
Non-PEO NEO Average Total Compensation Amount | $ 7,211,427 | 7,358,134 | 6,736,942 |
Non-PEO NEO Average Compensation Actually Paid Amount | $ 12,777,767 | 5,869,521 | 5,571,375 |
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | Summary Compensation Table to Compensation Actually Paid Reconciliation Table Required Adjustments to Summary Compensation Table (“SCT”) Totals to Determine Year SCT SCT Value SCT Value of $) Fair Value as Year-Over-Year Increase CAP Formula and A B C D E F G=A-B-C+D+E+F Robert A. Bradway 2022 21,399,733 11,138,544 4,773,714 20,800,961 11,751,273 3,615,844 41,655,553 2021 21,721,154 11,138,622 4,773,710 13,805,997 (2,572,161 ) (1,930 ) 17,040,728 2020 20,131,408 10,079,676 4,319,993 13,341,787 (3,546,758 ) (802,456 ) 14,724,312 Average of Other NEOs 2022 7,211,427 3,184,719 1,364,984 5,947,522 3,219,024 949,497 12,777,767 2021 7,358,134 3,246,014 1,391,226 4,023,392 (640,566 ) (234,199 ) 5,869,521 2020 6,736,942 2,834,702 1,214,968 3,752,153 (650,362 ) (217,688 ) 5,571,375 | ||
Compensation Actually Paid vs. Total Shareholder Return [Text Block] | (1) | ||
Compensation Actually Paid vs. Net Income [Text Block] | (2) | ||
Compensation Actually Paid vs. Company Selected Measure [Text Block] | (3) | ||
Total Shareholder Return Vs Peer Group [Text Block] | (1) | ||
Tabular List [Table Text Block] | 2022 Performance Measures Pursuant to Item 402(v) of Regulation S-K, non-financial • Non-GAAP • Non-GAAP • • • Non-GAAP • • | ||
Total Shareholder Return Amount | $ 119.07 | 98.87 | 98.01 |
Peer Group Total Shareholder Return Amount | 140.14 | 126.48 | 102.57 |
Net Income (Loss) | $ 6,552,000,000 | $ 5,893,000,000 | $ 7,264,000,000 |
Company Selected Measure Amount | 17.69 | 17.1 | 16.6 |
PEO Name | Mr. Bradway | ||
Measure [Axis]: 1 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Non-GAAP earnings per share (EPS) | ||
Non-GAAP Measure Description [Text Block] | Non-Generally non-GAAP, Appendix B | ||
Measure [Axis]: 2 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Non-GAAP return on invested capital (ROIC) | ||
Measure [Axis]: 3 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Total shareholder return (TSR) relative to that of the S&P 500 | ||
Measure [Axis]: 4 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Revenues | ||
Measure [Axis]: 5 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Non-GAAP net income | ||
Measure [Axis]: 6 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Pipeline, clinical study, and regulatory goals | ||
Measure [Axis]: 7 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Environmental, social, and governance goals | ||
PEO [Member] | SCT Value Of Stock Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | $ 11,138,544 | $ 11,138,622 | $ 10,079,676 |
PEO [Member] | SCT Value Of Option Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 4,773,714 | 4,773,710 | 4,319,993 |
PEO [Member] | Fair Value As Of Year End Of Equity Awards Granted During The Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 20,800,961 | 13,805,997 | 13,341,787 |
PEO [Member] | Year Over Year Increase Decrease In Fair Value As Of Year End Of Unvested Awards Granted In Prior Years [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 11,751,273 | (2,572,161) | (3,546,758) |
PEO [Member] | Increase Decrease From Prior Year End In Fair Value Of Awards That Vested During The Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 3,615,844 | (1,930) | (802,456) |
Non-PEO NEO [Member] | SCT Value Of Stock Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 3,184,719 | 3,246,014 | 2,834,702 |
Non-PEO NEO [Member] | SCT Value Of Option Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 1,364,984 | 1,391,226 | 1,214,968 |
Non-PEO NEO [Member] | Fair Value As Of Year End Of Equity Awards Granted During The Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 5,947,522 | 4,023,392 | 3,752,153 |
Non-PEO NEO [Member] | Year Over Year Increase Decrease In Fair Value As Of Year End Of Unvested Awards Granted In Prior Years [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 3,219,024 | (640,566) | (650,362) |
Non-PEO NEO [Member] | Increase Decrease From Prior Year End In Fair Value Of Awards That Vested During The Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | $ 949,497 | $ (234,199) | $ (217,688) |